WebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public... WebNov 17, 2024 · NEWARK, Calif., Nov. 17, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative...
Did you know?
WebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public ... WebSep 5, 2024 · Earnings Estimate Revisions for CymaBay Therapeutics Inc. For the fiscal year ending December 2024, this company is expected to earn -$1.21 per share, which is a change of 4.7% from the year-ago ...
WebJan 24, 2024 · Shares of CymaBay Therapeutics Inc. climbed 12%, to $7.43, in premarket trading after the company's underwritten stock offering priced at $7 a share. The clinical-stage biopharmaceutical company ... WebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $7.00 per share, and the pre-funded warrants are being sold at a public offering price of $6.9999 per underlying share.
WebJan 30, 2024 · CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a... WebAug 2, 2024 · NEWARK, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
WebJan 30, 2024 · Additional risks relating to CymaBay are contained in CymaBay's filings with the SEC, including without limitation its Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 14, 2024, and other documents subsequently filed with or furnished to the SEC, including the final prospectus supplement related to the …
WebJul 14, 2015 · CymaBay anticipates using the net proceeds from the offering for general corporate purposes, including clinical trials, research and development, capital expenditures and working capital. Piper... daddy u misspelled fatherWebNEWARK, CA -- (Marketwired) -- 07/15/15 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today the pricing of its underwritten public offering of 7,120,000 shares of its common stock at a price to the public of $2.81 per share, for expected gross proceeds of approximately $20 million. daddy\u0027s working boots by dolly partonWebNov 7, 2024 · NEWARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, … binson\u0027s lift chairsWebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public... daddy underwear men companyWebJan 23, 2024 · CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size … daddy urban dictionaryWebThe offering is expected to close on February 1, 2024, subject to the satisfaction of customary closing conditions. ... The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). binson\\u0027s livonia hoursWebJan 23, 2024 · CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. daddy valentine shirt